← Home
Daiichi Sankyo
-4.06%
Pharma / Pharmaceuticals, Biotechnology
Press Releases
| Date | Press release |
|---|---|
| 2025-01-30 23:05:00 | Daiichi Sankyo Appoints Hiroyuki Okuzawa As Chief Executive Officer Tokyo--(business wire)--daiichi sankyo company, ltd (tse: 4568) has appointed hiroyuki okuzawa, 62, to succeed sunao manabe, dvm, ph.d. as chief executive officer (ceo), effective april 1, 2025. dr. manabe will transition from his current role of representative director, executive chairperson and ceo to representative director and executive chairperson while mr. okuzawa will transition to representative director, president and ceo. under dr. manabe’s leadership, daiichi sankyo’s pioneering scie. |
| 2025-01-13 11:00:00 | Daiichi Sankyo Acquires Intellectual Property Rights For Anti-ta-muc1 Antibody In Ds-3939 From Glycotope Gmbh Tokyo & basking ridge, n.j.--(business wire)--daiichi sankyo company, ltd (tse: 4568) announced today that it will pay glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (ta-muc1) antibody, gatipotuzumab. such payment by daiichi sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. in 2018, daiichi s. |
| 2024-08-31 11:00:00 | Daiichi Sankyo Shines A Light On Inequalities And Unmet Needs In Care As Part Of Its Commitment To People With Cardiovascular Disease Munich--(business wire)--daiichi sankyo europe, (hereafter, daiichi sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (cv) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. the announcement follows the presentation of data from sub-analyses of the santorini observational study and etna-af (edoxaban treatment in routine clinical practice in patients with nonvalvular atrial fibrill. |
| 2024-07-10 06:06:00 | Daiichi Sankyo Opens New Affiliate For Oncology In Greece Athens, greece--(business wire)--daiichi sankyo (tse: 4568) today announced that it has opened a new affiliate for its oncology business in athens, greece. the establishment highlights the company’s strong commitment to addressing treatment needs of people living with cancer in the european region. thomais konstantopoulou has been appointed country manager, daiichi sankyo greece single member s.a. “we are very happy to open yet another new affiliate in europe to bring our innovative medicines t. |
| 2024-05-27 21:00:00 | Revolka Signed Master Service Agreement With Daiichi Sankyo Tokyo--(business wire)--revolka ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (norio hamamatsu, president and ceo) signed a master service agreement with daiichi sankyo co., ltd. (hiroyuki okuzawa, president and coo). revolka will create and deliver highly functional proteins, in collaboration with daiichi sankyo co., ltd. by using its proprietary protein engineering platform technology, called aiprotein®: a robust directed protein evol. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal